Related Experiment Video

Updated: Jun 17, 2026

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

Targeting focal adhesion kinase signaling in tumor growth and metastasis

Joerg Schwock1, Neesha Dhani, David W Hedley

  • 1Princess Margaret Hospital/Ontario Cancer Institute (PMH/OCI), Toronto M5G 2M9, Ontario, Canada.

Expert Opinion on Therapeutic Targets
|December 17, 2009
PubMed
Abstract

Insights

Focal adhesion kinase (FAK) is a promising cancer target. Inhibiting FAK may slow tumor growth and spread with few side effects, warranting further clinical investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Focal adhesion kinase (FAK) is central to integrin and growth factor signaling pathways.
  • Elevated FAK expression correlates with increased cancer cell migration, proliferation, and survival.
  • FAK, located in focal adhesions, is a key regulator of cell-matrix interactions.

Purpose of the Study:

  • To review current research on FAK as a cancer therapeutic target.
  • To assess the potential of various FAK-targeting strategies in cancer therapy.
  • To summarize evidence linking FAK biology to therapeutic outcomes.

Main Methods:

  • Examination of historical evidence supporting FAK as an anti-cancer target.
  • Summarization of diverse approaches to interfere with FAK signaling.
  • Discussion of FAK inhibitor combinations with other therapies.

Main Results:

  • FAK signaling interference demonstrates a link to anti-cancer effects.
  • The review synthesizes findings on FAK's role in tumor progression.
  • An informed perspective on FAK's future as a therapeutic target is presented.

Conclusions:

  • FAK inhibition shows potential for limiting cancer growth and progression with minimal toxicity.
  • Further clinical studies of small molecule FAK inhibitors are recommended.
  • Exploring combinations with existing therapies and identifying predictive biomarkers are crucial next steps.

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...